Pulmonx Corporation (LUNG)
| Previous Close | 6.79 |
| Open | 6.80 |
| Bid | 6.64 x 600 |
| Ask | 6.72 x 300 |
| Day's Range | 6.61 - 7.09 |
| 52 Week Range | 5.46 - 14.84 |
| Volume | |
| Avg. Volume | 236,190 |
| Market Cap | 263.384M |
| Beta (5Y Monthly) | 0.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.47 |
| Earnings Date | Feb 19, 2025 - Feb 24, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.50 |
ZacksDoes Pulmonx (LUNG) Have the Potential to Rally 117.74% as Wall Street Analysts Expect?
The consensus price target hints at an 117.7% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GlobeNewswirePulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York on Wednesday, December 4, 2024, at 9:30 AM PT / 12:30 PM ET. A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://inv
